Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, Shen J, Gururajan M, Sievert M, Stadler WM.

Prostate. 2016 Feb 15;76(3):286-93. doi: 10.1002/pros.23119. Epub 2015 Oct 23.

2.

Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.

Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE.

Oncotarget. 2015 Apr 30;6(12):10175-94.

3.

Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes.

Verweij FJ, de Heus C, Kroeze S, Cai H, Kieff E, Piersma SR, Jimenez CR, Middeldorp JM, Pegtel DM.

J Extracell Vesicles. 2015 Apr 10;4:26334. doi: 10.3402/jev.v4.26334. eCollection 2015.

4.

MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells.

Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM, Ben-Aharon I, Shalgi R.

Oncoscience. 2014 Apr 30;1(4):250-61. eCollection 2014.

5.

CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.

6.

Molecular pathways and targets in prostate cancer.

Shtivelman E, Beer TM, Evans CP.

Oncotarget. 2014 Sep 15;5(17):7217-59. Review.

7.

SRC: marker or actor in prostate cancer aggressiveness.

Vlaeminck-Guillem V, Gillet G, Rimokh R.

Front Oncol. 2014 Aug 18;4:222. doi: 10.3389/fonc.2014.00222. eCollection 2014. Review.

8.

Engineered kinase activation reveals unique morphodynamic phenotypes and associated trafficking for Src family isoforms.

Chu PH, Tsygankov D, Berginski ME, Dagliyan O, Gomez SM, Elston TC, Karginov AV, Hahn KM.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12420-5. doi: 10.1073/pnas.1404487111. Epub 2014 Aug 12.

9.

Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.

Gelman IH, Peresie J, Eng KH, Foster BA.

Mol Cancer Res. 2014 Oct;12(10):1470-9. doi: 10.1158/1541-7786.MCR-13-0490-T. Epub 2014 Jul 22.

10.

Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases.

Gelman IH.

Int J Biol Sci. 2014 Jun 5;10(6):620-6. doi: 10.7150/ijbs.8264. eCollection 2014. Review.

11.

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.

Udyavar AR, Hoeksema MD, Clark JE, Zou Y, Tang Z, Li Z, Li M, Chen H, Statnikov A, Shyr Y, Liebler DC, Field J, Eisenberg R, Estrada L, Massion PP, Quaranta V.

BMC Syst Biol. 2013;7 Suppl 5:S1. doi: 10.1186/1752-0509-7-S5-S1. Epub 2013 Dec 9.

12.

Src signaling pathways in prostate cancer.

Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG.

Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606. doi: 10.1007/s10555-013-9481-1. Review.

13.

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.

Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR.

Oncotarget. 2014 Feb 15;5(3):775-87.

14.

Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.

Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, Distelhorst CW, Lathia JD, Rich JN, Kappes JC, Gladson CL.

PLoS One. 2013 Aug 2;8(8):e70804. doi: 10.1371/journal.pone.0070804. Print 2013.

15.
16.

Src, p130Cas, and Mechanotransduction in Cancer Cells.

Matsui H, Harada I, Sawada Y.

Genes Cancer. 2012 May;3(5-6):394-401. doi: 10.1177/1947601912461443.

17.

Functions of the Lyn tyrosine kinase in health and disease.

Ingley E.

Cell Commun Signal. 2012 Jul 17;10(1):21. doi: 10.1186/1478-811X-10-21.

18.

Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells.

Martinez HD, Hsiao JJ, Jasavala RJ, Hinkson IV, Eng JK, Wright ME.

Genes Cancer. 2011 Oct;2(10):956-78. doi: 10.1177/1947601912436422.

19.

Oncogene-mediated alterations in chromatin conformation.

Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8. doi: 10.1073/pnas.1112570109. Epub 2012 May 21.

20.

Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.

Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR.

Clin Cancer Res. 2012 May 15;18(10):2850-60. doi: 10.1158/1078-0432.CCR-11-2486. Epub 2012 Apr 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk